IceCure Medical Ltd

NasdaqCM ICCM

IceCure Medical Ltd Net Income for the year ending December 31, 2023: USD -14.65 M

IceCure Medical Ltd Net Income is USD -14.65 M for the year ending December 31, 2023, a 14.90% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

IceCure Medical Ltd Net Income for the year ending December 31, 2022 was USD -17.22 M, a -71.04% change year over year.
IceCure Medical Ltd Net Income for the year ending December 31, 2021 was USD -10.07 M, a -110.71% change year over year.
IceCure Medical Ltd Net Income for the year ending December 31, 2020 was USD -4.78 M, a -0.35% change year over year.
IceCure Medical Ltd Net Income for the year ending December 31, 2019 was USD -4.76 M, a -34.70% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: ICCM

IceCure Medical Ltd

CEO	Mr. Eyal Shamir
IPO Date	Aug. 26, 2021
Location	Israel
Headquarters	7 Ha’Eshel Street
Employees	71
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Key trends

Past 5 years